Welcome to the e-CCO Library Archive!
I. Nieminen1, H. Huhtala2, M. Hyöty1, P. Collin1, P. Aitola1, 1Tampere University Hospital, Gastroenterology and alimentary tract surgery, Tampere, Finland, 2University of Tampere, Finland
Early treatment with infliximab for Crohn's disease patients
G. Pineton de Chambrun*1, L. Libier2, M. Nachury2, M. Collins3, D. Koriche4, C. Gower-Rousseau5, P. Zerbib4, A. Cortot6, J.-F. Colombel7, P. Desreumaux2
1Montpellier 1 University, Gastroenterology and Hepatology, Montpellier, France, 2CHU de Lille, Department of Gastroenterology, Lille, France, 3APHP Paris Sud University , Gastroenterology, Le Kremlin Bicêtre, France, 4Lille University Hospital, Colorectal Surgery Department , Lille, France, 5Lille University Hospital, North of France University, Epidemiology, Lille, France, 6Lille University Hospital, North of France University, Gastroenterology, Lille, France, 7Mount Sinai Hospital, Gastroenterology, New-York, United States
Severe scalp and skin involvement in Crohn's disease patients under treatment with anti-tumor necrosis factor alpha
E. Rodrigues-Pinto1, F. Magro1, F. Osório2, S. Lopes1, S. Magina2, G. Macedo1, 1Centro Hospitalar São João, Gastroenterology Department, Porto, Portugal, 2Centro Hospitalar São João, Dermatology, Porto, Portugal
M.K. Choi1, G.A. Song1, D.U. Kim1, D.Y. Ryu1, 1Pusan National University College of Medicine, Internal Medicine, Busan, South Korea
Patient perception towards faecal microbiota transplantation for treatment of Inflammatory Bowel Disease
N. Quraishi1, M. McMillan1, M. Widlak*1, L. Nell1, K. Quraishi2, S. Pathmakanthan1, N. Sharma2, T. Iqbal1
1University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Gastroenterology, Birmingham, United Kingdom, 2Heart of England NHS Foundation Trust, Heartlands Hospital, Gastroenterology, Birmingham, United Kingdom
Serum infliximab levels and early mucosal healing in Crohn's disease
J. Tang, X. Gao, M. Zhi, H. Zhou, H. Chen, M. Zhang, Q. Yang, Z. Liang, The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China
C.H. Choi1, K.H. Lee1, S.K. Chang1, W.H. Kim2, Y.H. Kim3, 1Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea, 2Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea, 3Sungkyunkwan University College of Medicine, South Korea
How could female infertility be reduced after open IPAA
T. Emmanouil*1, C. Christou2, A. Chatziioannou3, E. Falidas2, C. Vardas2, N. Kontoravdis2, S. Baratsis2
1Iaso General Hospital, Department of Gastroenterology and Surgery, Athens, Greece, 2Iaso General Hospital, Department of Gastroenterology and Surgery, Athens, Greece, 3National Hellenic Research Foundation, Institute of Biological Research &Biotechnology, Athens, Greece
Serum calprotectin: a novel biomarker to predict outcome in acute severe ulcerative colitis?
N.C. Hare1,2, N.A. Kennedy2,3, R. Kalla2,3, K. Kingstone4, I.D.R. Arnott2, A.G. Shand2, K. Palmer2, I. Penman5, C.W. Lees2,3, J. Satsangi2,3, 1Taunton and Somerset NHS Foundation Trust, Department of Gastroenterology, Taunton, United Kingdom, 2Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 3University of Edinburgh, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom, 4Western General Hospital, Department of Clinical Biochemistry, Edinburgh, United Kingdom, 5Royal Infirmary of Edinburgh, Endoscopy Unit, Centre for Liver and Digestive Disorders, Edinburgh, United Kingdom
G. D'Haens1, D.T. Rubin2, S. Inglis3, E. Magee4, P. Streck4, D. Solomon4, on behalf of the Ulcerative Colitis Remission Study Group, 1Academic Medical Center, Amsterdam, Netherlands, 2University of Chicago Inflammatory Bowel Disease Center, Chicago, IL, United States, 3Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom, 4Shire Development LLC, Wayne, PA, United States
Consensus Statements on the Management of Acute Severe Ulcerative Colitis
J.-H. Chen1, C. Corte1, V. Kariyawasam2, N. Moran1, P. Gounder1, G. Collins1, S. Connor3, T.W. Lee4, A. Walsh5, C.E. Koh6, 7, J. Chang1, S. Paramsothy8, S. Tattersall9, D.A. Lemberg10, 11, A. McLachlan12, 13, G. Moore14, J. Andrews15, R. Leong*1
1Concord Repatriation General Hospital, Gastroenterology & Hepatology, Sydney, Australia, 2Blacktown Hospital, Gastroenterology & Hepatology, Sydney, Australia, 3Liverpool Hospital, Gastroenterology & Hepatology, Sydney, Australia, 4Wollongong Hospital, Gastroenterology & Hepatology, Wollongong, Australia, 5St. Vincent Hospital, Gastroenterology & Hepatology, Sydney, Australia, 6Royal Prince Alfred Hospital, Colon & Rectal Surgery, Sydney, Australia, 7Royal Prince Alfred Hospital, Surgical Outcomes Research Centre, Sydney, Australia, 8University of New South Wales, St Vincent's Clinical School, Faculty of Medicine, Sydney, Australia, 9Ryde Hospital, Gastroenterology, Sydney, Australia, 10Sydney Children's Hospital, Paediatric Gastroenterology, Sydney, Australia, 11University of New South Wales, Woman's and Children's Health, Sydney, Australia, 12The University of Sydney, Faculty of Pharmacy, Sydney, Australia, 13Concord Repatriation General Hospital, Centres for Education and Research on Ageing, Sydney, Australia, 14Monash University & Monash Health, Gastroenterology & Hepatology, Clayton, Melbourne, Australia, 15Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia
Serum CRP is a better early marker for response to infliximab induction therapy than fecal calprotectin in patients with moderate to severe ulcerative colitis
J.F. Brandse1, J.M. Jansen2, P.A. Baars3, M. Löwenberg1, C.Y. Ponsioen1, G.R. van den Brink1, G. D'Haens1, 1Academic Medical Center, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 2Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 3Academic Medical Center, Clinical Immunology, Amsterdam, Netherlands